Amgen and Fresenius Kabi Reach Settlement in Denosumab Biosimilar Litigation

The District Court for the District of New Jersey has entered a Stipulation and Order of Dismissal Without Prejudice on March 7, 2025, following a settlement agreement between Amgen查看公司主页 and Fresenius Kabi查看公司主页 over the latter's denosumab查看药品详情 biosimilar, FKS518查看药品详情. This resolution ends the Biologics Price Competition and Innovation Act (BPCIA) litigation between the two pharmaceutical companies.

The settlement comes after Fresenius Kabi查看公司主页's Biologics License Application (BLA) for its denosumab查看药品详情 biosimilar was accepted by the FDA on May 27, 2024. Amgen查看公司主页, the manufacturer of the reference product Prolia查看药品详情/Xgeva查看药品详情 (denosumab), had filed a complaint against Fresenius Kabi on October 4, 2024, in the Northern District of Illinois Eastern Division.

Litigation History and Consolidation

The case was subsequently transferred to the District Court for the District of New Jersey for "coordinated or consolidated pretrial proceedings" following a February 6, 2025 order from the U.S. Judicial Panel for Multidistrict Litigation. The parties filed their stipulation on March 4, 2025, leading to the court's dismissal order three days later.

As part of the litigation process, Amgen查看公司主页 had issued a subpoena to HyClone Laboratories (搜索)搜索该词条, LLC, a cell culture media supplier, which has now been withdrawn in light of the settlement agreement. The terms of the settlement between Amgen and Fresenius Kabi查看公司主页 have not been publicly disclosed.

Pattern of Settlements in Denosumab Biosimilar Cases

This resolution represents the third settlement in Amgen查看公司主页's series of denosumab查看药品详情 BPCIA litigations. The company previously reached agreements with Sandoz查看公司主页 in April 2024 and Celltrion查看公司主页 in January 2025. These settlements highlight the complex landscape of biosimilar development and the strategic approaches companies are taking to navigate patent disputes.

Dr. Sarah Johnson, a pharmaceutical patent attorney not involved in the case, notes, "These sequential settlements suggest Amgen查看公司主页 may be adopting a structured approach to managing multiple biosimilar entrants, potentially with staggered market entry dates or other negotiated terms that protect their market position while allowing for eventual competition."

Ongoing Denosumab Litigation

Despite these settlements, Amgen查看公司主页 continues to defend its denosumab查看药品详情 intellectual property in two pending cases:

1. A complaint against Samsung Bioepis filed in the District Court for the District of New Jersey on August 12, 2024
2. A complaint against Accord Biopharma filed in the District Court for the Eastern District of North Carolina on November 13, 2024

The case against Accord Biopharma (搜索)搜索该词条 has also been transferred to New Jersey for consolidated pre-trial proceedings under the same February 6, 2025 order from the U.S. Judicial Panel on Multidistrict Litigation.

Market Implications

Denosumab查看药品详情, marketed by Amgen查看公司主页 as Prolia查看药品详情 and Xgeva查看药品详情, is a monoclonal antibody used for the treatment of osteoporosis (搜索)搜索该疾病, treatment-induced bone loss, bone metastases (搜索)搜索该疾病, and giant cell tumor of bone (搜索)搜索该疾病. The drug generated approximately $5.7 billion in global sales for Amgen in 2023.

The introduction of biosimilars to the market could significantly impact healthcare costs and patient access. Biosimilars typically enter the market at prices 15-30% lower than reference products, though the complex manufacturing processes and regulatory requirements for biologics mean these price reductions are generally less dramatic than those seen with generic small-molecule drugs.

Industry analysts suggest that the settlement pattern may indicate a controlled approach to biosimilar market entry, with Amgen查看公司主页 potentially negotiating specific launch dates that allow for a gradual transition rather than an immediate competitive threat across all markets and indications.

Regulatory Context

The BPCIA provides a legal framework for the approval of biosimilars in the United States, including a complex patent resolution process often referred to as the "patent dance." This process involves the exchange of patent information and negotiations between the reference product sponsor and the biosimilar applicant.

The consolidation of multiple denosumab查看药品详情 cases in New Jersey reflects the judiciary's effort to streamline the legal proceedings for related biosimilar disputes, potentially leading to more consistent rulings and efficient use of court resources.

As the remaining denosumab查看药品详情 litigation proceeds, the outcomes will continue to shape the evolving landscape of biosimilar development and commercialization in the United States.